All lobbying filings

EDWARDS LIFESCIENCES, LLC

Lobbying for EDWARDS LIFESCIENCES LLC

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · California · House · Senate · $360,000.00 expenses · posted Jul 18, 2025

Official filing document

Bills named in this filing 1

S 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Lobbying activity 4

Health Issues

Ensuring Patient Access to Critical Breakthrough Products (S.1717) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development

Medicare/Medicaid

CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (s.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development

Taxation/Internal Revenue Code

Corporate Tax Reform Proposals

Trade (domestic/foreign)

Tariffs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.